A Stimuli-Responsive Small-Molecule Metal-Carrying Prochelator: A Novel Prodrug Design Strategy for Metal Complexes

Angew Chem Int Ed Engl. 2022 Jul 11;61(28):e202203500. doi: 10.1002/anie.202203500. Epub 2022 May 20.

Abstract

Selective activation of prodrugs is an important approach to reduce the side effects of disease treatment. We report a prodrug design concept for metal complexes, termed "metal-carrying prochelator", which can co-carry a metal ion and chelator within a single small-molecule compound and remain inert until it undergoes a specifically triggered intramolecular chelation to synthesize a bioactive metal complex in situ for targeted therapy. As a proof-of-concept, we designed a H2 O2 -responsive small-molecule prochelator, DPBD, based on the strong chelator diethyldithiocarbamate (DTC) and copper. DPBD can carry Cu2+ (DPBD-Cu) and respond to elevated H2 O2 levels in tumor cells by releasing DTC, which rapidly chelates Cu2+ from DPBD-Cu affording a DTC-copper complex with high cytotoxicity, realizing potent antitumor efficacy with low systemic toxicity. Thus, with its unique intramolecularly triggered activation mechanism, this concept based on a small-molecule metal-carrying prochelator can help in the prodrug design of metal complexes.

Keywords: Copper Carriers; Disulfiram; Metal Complexes; Prochelator; Prodrug.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Chelating Agents / pharmacology
  • Coordination Complexes* / pharmacology
  • Copper / pharmacology
  • Metals
  • Prodrugs* / pharmacology
  • Prodrugs* / therapeutic use

Substances

  • Chelating Agents
  • Coordination Complexes
  • Metals
  • Prodrugs
  • Copper